SCHEMBL8530

SCHEMBL8530

OCc1ccccc1B(O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.55
APOBEC3G Q9HC16 1/20 0.44
ENPP2 Q13822 3/20 0.43
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
LIPE Q05469 1/20 0.39
MAPT P10636 1/20 0.39
ORAI1 Q96D31 1/20 0.37
ORAI2 Q96SN7 1/20 0.37
ORAI3 Q9BRQ5 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
TSHR P16473 1/20 0.36
CYP2A6 P11509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377890 1.00 LIPG (0.55) LIPGAPOBEC3GENPP2PDCD1CD274
Water SCHEMBL3179940 0.98 LIPG (0.53) LIPGAPOBEC3GENPP2PDCD1CD274
SCHEMBL2562458 0.93 LIPG (0.50) LIPGAPOBEC3GENPP2PDCD1CD274
SCHEMBL15077351 0.83 APOBEC3G (0.43) LIPGAPOBEC3GENPP2PDCD1CD274
SCHEMBL29845752 0.81 LIPG (0.62) LIPGENPP2LIPEORAI1ORAI2
SCHEMBL2560981 0.81 LIPG (0.62) LIPGENPP2LIPEORAI1ORAI2
SCHEMBL29468961 0.80 LIPG (0.61) LIPGENPP2LIPEMAPT
SCHEMBL410387 0.80 LIPG (0.61) LIPGENPP2LIPEMAPT
SCHEMBL5840438 0.79 PDCD1 (0.52) LIPGAPOBEC3GENPP2PDCD1CD274
SCHEMBL29955362 0.79 LIPG (0.41) LIPGAPOBEC3GENPP2PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 886 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12447133-B2 Composition and device for preventing hypoglycemia and use thereof THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2025-10-21 US claimed
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
CN-116239562-B Method for synthesizing doxepin hydrochloride by taking benzofuranone as raw material 江苏师范大学 2024-12-31 CN claimed
CN-116271202-B Rapid self-repairing injectable nano composite antibacterial hydrogel dressing and preparation method thereof 河南科技大学 2024-06-25 CN claimed
CN-118164893-A Pentamethine cyanine dye, synthesis and application 中国科学院大连化学物理研究所 2024-06-11 CN claimed
CN-115403898-B Phenolic resin suitable for RTM process and preparation method and application thereof 西安交通大学 2023-12-19 CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 WO claimed
EP-2307398-A1 POLYMERISABLE COMPOUNDS FOR MAKING OPTO-ELECTRONIC DEVICES IMEC (BE) 2011-04-13 EP claimed
US-20110059040-A1 COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-03-10 US claimed
EP-2173362-A2 COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY University Of Utah (US) 2010-04-14 EP claimed
WO-2010000504-A1 POLYMERISABLE COMPOUNDS FOR MAKING OPTO-ELECTRONIC DEVICES INTERUNIVERSITAIR MICROELEKTRONICA CENTRUM (BE) 2010-01-07 WO claimed
WO-2009003090-A2 COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY UNIVERSITY OF UTAH (US) 2008-12-31 WO claimed
EP-0765331-B1 OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES AVECIA LTD (GB) 2000-08-09 EP claimed
US-5880188-A PROTECTING MEDIUM SUSCEPTIBLE TO MICROBIAL ATTACK BY TREATING WITH SPECIFIED OXABOROLE COMPOUND ZENECA LIMITED (GB) 1999-03-09 US claimed
EP-0765331-A1 OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES ZENECA LIMITED (GB) 1997-04-02 EP claimed
WO-1995033754-A1 OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES ZENECA LIMITED (GB) 1995-12-14 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059040-A1 COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY BLVRB, RNASE1, BPGM LIPG 167/4885APOBEC3G 626/4885ENPP2 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.